150 related articles for article (PubMed ID: 21693769)
1. Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis.
Fasol U; Frost A; Büchert M; Arends J; Fiedler U; Scharr D; Scheuenpflug J; Mross K
Ann Oncol; 2012 Apr; 23(4):1030-6. PubMed ID: 21693769
[TBL] [Abstract][Full Text] [Related]
2. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP
J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
Hirashima Y; Yamada Y; Tateishi U; Kato K; Miyake M; Horita Y; Akiyoshi K; Takashima A; Okita N; Takahari D; Nakajima T; Hamaguchi T; Shimada Y; Shirao K
Int J Cancer; 2012 May; 130(10):2359-65. PubMed ID: 21780098
[TBL] [Abstract][Full Text] [Related]
5. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial.
Kim YE; Joo B; Park MS; Shin SJ; Ahn JB; Kim MJ
Cancer Res Treat; 2016 Oct; 48(4):1210-1221. PubMed ID: 26987390
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic therapy with contrast-enhanced ultrasound in colorectal cancer patients with liver metastasis.
Wu Z; Yang X; Chen L; Wang Z; Shi Y; Mao H; Dai G; Yu X
Medicine (Baltimore); 2017 May; 96(20):e6731. PubMed ID: 28514289
[TBL] [Abstract][Full Text] [Related]
7. Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy.
Tampellini M; Gned D; Baratelli C; Brizzi MP; Ottone A; Alabiso I; Bertaggia C; Di Maio M; Scagliotti GV; Veltri A
Radiol Med; 2016 Dec; 121(12):950-957. PubMed ID: 27601143
[TBL] [Abstract][Full Text] [Related]
8. Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver Metastases.
Kannan P; Kretzschmar WW; Winter H; Warren D; Bates R; Allen PD; Syed N; Irving B; Papiez BW; Kaeppler J; Markelc B; Kinchesh P; Gilchrist S; Smart S; Schnabel JA; Maughan T; Harris AL; Muschel RJ; Partridge M; Sharma RA; Kersemans V
Clin Cancer Res; 2018 Oct; 24(19):4694-4704. PubMed ID: 29959141
[No Abstract] [Full Text] [Related]
9. Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate.
Vriens D; van Laarhoven HW; van Asten JJ; Krabbe PF; Visser EP; Heerschap A; Punt CJ; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2009 Nov; 50(11):1777-84. PubMed ID: 19837750
[TBL] [Abstract][Full Text] [Related]
10. Diffusion-Related MRI Parameters for Assessing Early Treatment Response of Liver Metastases to Cytotoxic Therapy in Colorectal Cancer.
Kim JH; Joo I; Kim TY; Han SW; Kim YJ; Lee JM; Han JK
AJR Am J Roentgenol; 2016 Sep; 207(3):W26-32. PubMed ID: 27303858
[TBL] [Abstract][Full Text] [Related]
11. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil.
van Laarhoven HW; Klomp DW; Rijpkema M; Kamm YL; Wagener DJ; Barentsz JO; Punt CJ; Heerschap A
NMR Biomed; 2007 Apr; 20(2):128-40. PubMed ID: 17006886
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
Liu G; Rugo HS; Wilding G; McShane TM; Evelhoch JL; Ng C; Jackson E; Kelcz F; Yeh BM; Lee FT; Charnsangavej C; Park JW; Ashton EA; Steinfeldt HM; Pithavala YK; Reich SD; Herbst RS
J Clin Oncol; 2005 Aug; 23(24):5464-73. PubMed ID: 16027440
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional contrast enhanced ultrasound score and dynamic contrast-enhanced magnetic resonance imaging score in evaluating breast tumor angiogenesis: correlation with biological factors.
Jia WR; Chai WM; Tang L; Wang Y; Fei XC; Han BS; Chen M
Eur J Radiol; 2014 Jul; 83(7):1098-1105. PubMed ID: 24794865
[TBL] [Abstract][Full Text] [Related]
14. Mixed-effects modeling of clinical DCE-MRI data: application to colorectal liver metastases treated with bevacizumab.
Ferl GZ; O'Connor JP; Parker GJ; Carano RA; Acharya SJ; Jayson GC; Port RE
J Magn Reson Imaging; 2015 Jan; 41(1):132-41. PubMed ID: 24753433
[TBL] [Abstract][Full Text] [Related]
15. Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.
Amadori M; Barone D; Scarpi E; Oboldi D; Amadori E; Bandi G; Rossi A; Ferroni F; Ragazzini A; Casadei Gardini A; Frassineti GL; Gavelli G; Passardi A
Eur Radiol; 2018 Jul; 28(7):2969-2978. PubMed ID: 29417252
[TBL] [Abstract][Full Text] [Related]
16. Tumour subregion analysis of colorectal liver metastases using semi-automated clustering based on DCE-MRI: Comparison with histological subregions and impact on pharmacokinetic parameter analysis.
Franklin JM; Irving B; Papiez BW; Kallehauge JF; Wang LM; Goldin RD; Harris AL; Anderson EM; Schnabel JA; Chappell MA; Brady M; Sharma RA; Gleeson FV
Eur J Radiol; 2020 May; 126():108934. PubMed ID: 32217426
[TBL] [Abstract][Full Text] [Related]
17. Comparison of contrast-enhanced ultrasonograpy with Gd-EOB-DTPA-enhanced MRI in the diagnosis of liver metastasis from colorectal cancer.
Shiozawa K; Watanabe M; Ikehara T; Matsukiyo Y; Kogame M; Kikuchi Y; Otsuka Y; Kaneko H; Igarashi Y; Sumino Y
J Clin Ultrasound; 2017 Mar; 45(3):138-144. PubMed ID: 27861987
[TBL] [Abstract][Full Text] [Related]
18. Quantitative free-breathing dynamic contrast-enhanced MRI in hepatocellular carcinoma using gadoxetic acid: correlations with Ki67 proliferation status, histological grades, and microvascular density.
Chen J; Chen C; Xia C; Huang Z; Zuo P; Stemmer A; Song B
Abdom Radiol (NY); 2018 Jun; 43(6):1393-1403. PubMed ID: 28939963
[TBL] [Abstract][Full Text] [Related]
19. A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging.
Morgan B; Utting JF; Higginson A; Thomas AL; Steward WP; Horsfield MA
Br J Cancer; 2006 May; 94(10):1420-7. PubMed ID: 16670720
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.
Thomas AL; Morgan B; Drevs J; Unger C; Wiedenmann B; Vanhoefer U; Laurent D; Dugan M; Steward WP
Semin Oncol; 2003 Jun; 30(3 Suppl 6):32-8. PubMed ID: 12802793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
